BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

534 related articles for article (PubMed ID: 26152804)

  • 1. ALK and ROS1 rearrangements tested by fluorescence in situ hybridization in cytological smears from advanced non-small cell lung cancer patients.
    Bozzetti C; Nizzoli R; Tiseo M; Squadrilli A; Lagrasta C; Buti S; Gasparro D; Zanoni D; Majori M; De Filippo M; Mazzoni F; Maddau C; Naldi N; Sammarelli G; Frati C; Pinto C; Ardizzoni A
    Diagn Cytopathol; 2015 Nov; 43(11):941-6. PubMed ID: 26152804
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of a Dual ALK/ROS1 Fluorescent In Situ Hybridization Test in Non-Small-cell Lung Cancer.
    Ginestet F; Lambros L; Le Flahec G; Marcorelles P; Uguen A
    Clin Lung Cancer; 2018 Sep; 19(5):e647-e653. PubMed ID: 29801706
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiplex fluorescence in situ hybridisation to detect anaplastic lymphoma kinase and ROS proto-oncogene 1 receptor tyrosine kinase rearrangements in lung cancer cytological samples.
    Zito Marino F; Rossi G; Cozzolino I; Montella M; Micheli M; Bogina G; Munari E; Brunelli M; Franco R
    J Clin Pathol; 2020 Feb; 73(2):96-101. PubMed ID: 31562206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anaplastic lymphoma kinase gene rearrangements in cytological samples of non-small cell lung cancer: comparison with histological assessment.
    Proietti A; Alì G; Pelliccioni S; Lupi C; Sensi E; Boldrini L; Servadio A; Chella A; Ribechini A; Cappuzzo F; Miccoli M; Fontanini G
    Cancer Cytopathol; 2014 Jun; 122(6):445-53. PubMed ID: 24648382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of ROS1-positive non-small cell lung cancer on cytological specimens using immunocytochemistry.
    Vlajnic T; Savic S; Barascud A; Baschiera B; Bihl M; Grilli B; Herzog M; Rebetez J; Bubendorf L
    Cancer Cytopathol; 2018 Jun; 126(6):421-429. PubMed ID: 29451745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of methods in the detection of ALK and ROS1 rearrangements in lung cancer.
    Rogers TM; Russell PA; Wright G; Wainer Z; Pang JM; Henricksen LA; Singh S; Stanislaw S; Grille J; Roberts E; Solomon B; Fox SB
    J Thorac Oncol; 2015 Apr; 10(4):611-8. PubMed ID: 25789833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. On the relevance of a testing algorithm for the detection of ROS1-rearranged lung adenocarcinomas.
    Mescam-Mancini L; Lantuéjoul S; Moro-Sibilot D; Rouquette I; Souquet PJ; Audigier-Valette C; Sabourin JC; Decroisette C; Sakhri L; Brambilla E; McLeer-Florin A
    Lung Cancer; 2014 Feb; 83(2):168-73. PubMed ID: 24380695
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validation of ALK/ROS1 Dual Break Apart FISH Probe probe in non-small-cell lung cancer.
    Lim SM; Chang H; Cha YJ; Liang S; Tai YC; Li G; Pestova E; Policht F; Perez T; Soo RA; Park WY; Kim HR; Shim HS; Cho BC
    Lung Cancer; 2017 Sep; 111():79-83. PubMed ID: 28838404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biomarkers for ALK and ROS1 in Lung Cancer: Immunohistochemistry and Fluorescent In Situ Hybridization.
    Luk PP; Selinger CI; Mahar A; Cooper WA
    Arch Pathol Lab Med; 2018 Aug; 142(8):922-928. PubMed ID: 29902067
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma.
    Kim HR; Lim SM; Kim HJ; Hwang SK; Park JK; Shin E; Bae MK; Ou SH; Wang J; Jewell SS; Kang DR; Soo RA; Haack H; Kim JH; Shim HS; Cho BC
    Ann Oncol; 2013 Sep; 24(9):2364-70. PubMed ID: 23788756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiplex fluorescence in situ hybridization testing for anaplastic lymphoma kinase and c-ros oncogene 1 gene rearrangements on cytology smears in lung adenocarcinomas: comparative study with formalin-fixed paraffin-embedded sections.
    Nambirajan A; Rana D; Samant K; Prabakaran A; Malik P; Jain D
    J Am Soc Cytopathol; 2022; 11(3):154-164. PubMed ID: 35148960
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Screening of ROS1 rearrangements in lung adenocarcinoma by immunohistochemistry and comparison with ALK rearrangements.
    Cha YJ; Lee JS; Kim HR; Lim SM; Cho BC; Lee CY; Shim HS
    PLoS One; 2014; 9(7):e103333. PubMed ID: 25058391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discrepancies between FISH and immunohistochemistry for assessment of the ALK status are associated with ALK 'borderline'-positive rearrangements or a high copy number: a potential major issue for anti-ALK therapeutic strategies.
    Ilie MI; Bence C; Hofman V; Long-Mira E; Butori C; Bouhlel L; Lalvée S; Mouroux J; Poudenx M; Otto J; Marquette CH; Hofman P
    Ann Oncol; 2015 Jan; 26(1):238-244. PubMed ID: 25344360
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ROS1 rearrangements define a unique molecular class of lung cancers.
    Bergethon K; Shaw AT; Ou SH; Katayama R; Lovly CM; McDonald NT; Massion PP; Siwak-Tapp C; Gonzalez A; Fang R; Mark EJ; Batten JM; Chen H; Wilner KD; Kwak EL; Clark JW; Carbone DP; Ji H; Engelman JA; Mino-Kenudson M; Pao W; Iafrate AJ
    J Clin Oncol; 2012 Mar; 30(8):863-70. PubMed ID: 22215748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ALK status testing in non-small-cell lung carcinoma by FISH on ThinPrep slides with cytology material.
    Minca EC; Lanigan CP; Reynolds JP; Wang Z; Ma PC; Cicenia J; Almeida FA; Pennell NA; Tubbs RR
    J Thorac Oncol; 2014 Apr; 9(4):464-8. PubMed ID: 24736067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ALK and ROS1 testing on lung cancer cytologic samples: Perspectives.
    Pisapia P; Lozano MD; Vigliar E; Bellevicine C; Pepe F; Malapelle U; Troncone G
    Cancer Cytopathol; 2017 Nov; 125(11):817-830. PubMed ID: 28743163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Detection of ALK and ROS1 rearrangements by immunocytochemistry on cytological samples].
    Frankel D; Bourlard D; Garcia S; Robaglia-Schlupp A; Peker E; Groliere A; Kaspi E; Roll P
    Ann Pathol; 2019 Jun; 39(3):227-236. PubMed ID: 30709602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histopathologic characteristics of advanced-stage ROS1-rearranged non-small cell lung cancers.
    Park E; Choi YL; Ahn MJ; Han J
    Pathol Res Pract; 2019 Jul; 215(7):152441. PubMed ID: 31085007
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Next-generation Sequencing for ALK and ROS1 Rearrangement Detection in Patients With Non-small-cell Lung Cancer: Implications of FISH-positive Patterns.
    Clavé S; Rodon N; Pijuan L; Díaz O; Lorenzo M; Rocha P; Taus Á; Blanco R; Bosch-Barrera J; Reguart N; de la Torre N; Oliveras G; Espinet B; Bellosillo B; Puig X; Arriola E; Salido M
    Clin Lung Cancer; 2019 Jul; 20(4):e421-e429. PubMed ID: 30898567
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunohistochemistry, fluorescence in situ hybridization, and reverse transcription-polymerase chain reaction for the detection of anaplastic lymphoma kinase gene rearrangements in patients with non-small cell lung cancer: potential advantages and methodologic pitfalls.
    Demidova I; Barinov A; Savelov N; Gagarin I; Grinevitch V; Stroiakovaski D; Popov M; Laktionov K; Gutorov S; Smolin A; Olshanskaya Y; Obukhova T
    Arch Pathol Lab Med; 2014 Jun; 138(6):794-802. PubMed ID: 24878018
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.